Stock Analiz

Unicycive Therapeutics, Inc. UNCY

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$3.55Market cap $99M
Open the interactive analysis →

Unicycive Therapeutics, Inc. (UNCY) is a healthcare company listed in the US with a market value of about $99M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -144%.

About Unicycive Therapeutics

Unicycive Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 955% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B1.9
EV/EBITDA—
PEG—
Dividend yield—
FCF yield-28.2%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-3211.9%
ROIC (5-yr avg.)-144.0%
Profitable years (of last 10)0
Years paying a dividend2

Financials, last 6 years

Fiscal year202520242023202220212020
Revenue——$675000$951000——
Net income-$27M-$37M-$31M-$18M-$10M-$2M
Free cash flow-$31M-$29M-$18M-$16M-$6M—
EPS (diluted)$-1.67$-5.65$-12.80$-12.00$-8.60$-2.70
Net margin——-4525.0%-1898.8%——
ROIC-76.9%-312.8%——-42.2%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Unicycive Therapeutics pay a dividend?

Not currently.

Is Unicycive Therapeutics a good stock to buy?

We do not give buy or sell advice. Unicycive Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.